Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $77.71

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $77.71.

Several equities research analysts recently issued reports on the company. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th.

Insider Activity at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,781 shares of company stock valued at $2,465,372 over the last 90 days. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE boosted its position in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV boosted its position in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $166,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the period. Finally, Rafferty Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $200,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $59.99 on Friday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.26 billion, a P/E ratio of -109.07 and a beta of 0.74. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81. The stock’s 50 day simple moving average is $56.99 and its 200 day simple moving average is $58.23.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.